Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

L H Calabrese; N N Zein; D Vassilopoulos

doi:10.1136/ard.2005.043257

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

Ann Rheum Dis. 2006 Aug;65(8):983-9. doi: 10.1136/ard.2005.043257. Epub 2006 Apr 20.

Authors

L H Calabrese¹, N N Zein, D Vassilopoulos

Affiliation

¹ Department of Rheumatic and Immunological Disease, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, USA. [email protected]

Abstract

Understanding of the natural history and basic biology of hepatitis B virus (HBV) has increased greatly in recent years. In view of this, the following are reviewed here: (a) recent advances in HBV biology pertinent to the rheumatic disease population; (b) the risks of HBV reactivation in patients with rheumatic disease undergoing immunosuppression; and (c) potential strategies to manage these risks.

Publication types

Review

MeSH terms

Antirheumatic Agents / therapeutic use
Antiviral Agents / therapeutic use
Drug Therapy, Combination
Hepatitis B / complications
Hepatitis B / etiology*
Hepatitis B / prevention & control
Hepatitis B virus / physiology*
Humans
Immunocompromised Host*
Liver / immunology
Liver / virology
Rheumatic Diseases / drug therapy
Rheumatic Diseases / immunology*
Virus Activation*

Substances

Antirheumatic Agents
Antiviral Agents